Rodents eliminate antiepileptic drugs (AEDs) faster than humans, creating challenges for designing clinically relevant protocols. Half-lives of AEDs in immature mice are unknown. The pharmacokinetics of commonly used AEDs were examined in CD1 mice using a single-dose protocol at postnatal day 19. After intraperitoneal therapeutic dosing, blood serum concentrations spanning 1-48 h post-administration and corresponding brain tissue concentrations at 4 h were analyzed. Half-lives of valproate, phenobarbital, diazepam (and metabolites), phenytoin, and levetiracetam were 2. 6, 15.8, 22.3, 16.3, and 3.2 h, respectively, compared to 0.8, 7.5, 7.7, 16.0, and 1.5 h reported for adult mice. Brain-to-blood ratios were comparable with adult ratios. AEDs tested had longer half-lives and maintained therapeutic plasma concentrations longer than reported in mature mice, making clinically relevant protocols feasible.
Introduction
Neonatal stroke occurs approximately once per 4000 term births, and while most children survive their stroke, approximately 75% have sequelae including learning and memory problems. These strokes often present with seizures. In the pediatric population, strokes carry a significant risk of mortality and morbidity and also commonly present with seizures. They are commonly symptomatic, multifocal, and resistant to treatment with common antiepileptic drugs [1] . Anticonvulsants are commonly administered in the months after stroke; therefore, animal models are useful tools for the determination of consequences of this therapeutic stratagem [2] in the developing brain. Our group has earlier investigated the ischemic stroke after unilateral carotid ligation in CD1 neonatal mice and characterized the associated poststroke cognitive impairments [3] . With the intention of investigating the feasibility of designing effective drug administration protocols to evaluate the effects of anticonvulsants on the post-stroke developing brain, this study was undertaken.
Pediatric patients have faster drug absorption times, higher peak drug concentrations, and more rapid clearing of anticonvulsants, leading to more adverse effects, less effective seizure control, or both [4] . Recent literature using rodent models has indicated the existence of possible negative consequences of anticonvulsant administration for brain development and cognition. Increased apoptosis and decreased proliferation have been shown throughout the immature brain after anticonvulsant administration [5, 6] . Long-term cognitive deficits after neonatal drug administration have been shown through behavioral tests targeting water maze learning and memory tasks [6] . Models of seizures in the immature brain are needed to understand the mechanisms of anticonvulsant effects upon seizures and brain development.
Clinically, antiepileptic drugs are given chronically and must maintain a therapeutic trough concentration. Rodents eliminate drugs at a quicker rate than humans, challenging the creation of therapeutic chronic-dosing protocols, which would mimic clinical protocols. These protocols would help investigate hypotheses that provide insights into the effects of antiepileptic drugs on the developing brain. The shorter half-lives of commonly used antiepileptic drugs after single-dose administration have been reported for adult rats and mice (Table 1) , but pharmacokinetic data for immature rodents is lacking.
Concentrations of anticonvulsants in the human brain are developmentally dependent and different drug doses are efficacious at different ages [4] . Elements of the blood-brain barrier, and the tight junctions between the cerebral endothelial cells that make up the blood-brain barrier themselves, develop as the brain matures [15] . An associated decline in brain-to-blood ratios of small molecules has been shown during development [15] . Anticonvulsants also have different mechanisms to cross the blood-brain barrier through the various drug transporters [16] . At therapeutic plasma concentrations, brain penetrations of different antiepileptic drugs in mature mice are variable ( Table 2 ). Brain-to-blood ratio data for antiepileptic drugs in immature rodents is lacking.
This study evaluated serum concentrations at time points spanning 1-48 h, and brain concentrations at 4 h postinjection in CD1 mice on postnatal day 19 (P19).
Methods
All materials and methods were approved by the Johns Hopkins University Animal Care and Use Committee. Litters of CD1 mice were purchased from Charles River Laboratories Inc. (Wilmington, Massachusetts, USA), arrived at postnatal day 17 (P17), and acclimated for 2 days. Pups were housed in polycarbonate cages with the dam on a 12 h light : dark cycle; food was provided ad libitum.
Antiepileptic drugs
Diazepam, levetiracetam, phenobarbital (phenobarbital sodium salt), phenytoin (5,5-Diphenylhydantoin), and valproate (valproic acid sodium salt) were purchased from Sigma-Aldrich Co. (St Louis, Missouri, USA). Diazepam was reconstituted to 1 mg/ml in 100% ethanol, levetiracetam to 50 mg/ml in sterile dH 2 O, phenobarbital to 25 mg/ml in sterile dH 2 O, phenytoin to 25 mg/ml in 3 ml sterile dH 2 O with 1 ml 10N NaOH, and valproate to 100 mg/ml in sterile dH 2 O.
Drug administration and sample collection
Mice were injected intraperitoneally with a single dose of 1 mg/kg diazepam, 200 mg/kg levetiracetam, 60 mg/kg phenobarbital, 60 mg/kg phenytoin, or 200 mg/kg valproate. Doses necessary to achieve therapeutic efficacy in adult rodents were chosen [13] . On account of the limited total blood volume of neonatal mice, 19-day-old mice were used in this study, which allowed collection of blood sample volumes sufficient for individual quantification. The P19 mouse can be considered roughly equivalent to the juvenile human. Blood samples were obtained by open cardiac puncture to access the total blood volume, and sample collection occurred at times ranging from 1 to 48 h (n = 2-5 each) using a litter-based model [15] . Samples were centrifuged at 14 000g Â 15 min and serum was stored in sterilized EDTA tubes at 41C. At 4 h post-injection, corresponding brain samples [18] were harvested after transcardiac flushing with 0.9% NaCl. Brain samples were homogenized in 0.9% NaCl (1:5 w/v) and centrifuged at 10 000g Â 10 min at 41sC. Supernatants were collected and stored at -801C.
Sample analysis
Plasma samples and brain supernatants were thawed at room temperature. Benzodiazepines, phenobarbital, phenytoin, and valproate were assayed in plasma and in brain supernatants using an automated polarized immunofluorescence assay (PIFA, Abbott Diagnostics, Dallas, Texas, USA). The benzodiazepine antibody detects diazepam and its active metabolites desmethyldiazepam, oxazepam, and temazepam. Accordingly, results were reported as benzodiazepines.
Levetiracetam was detected in plasma and in brain supernatant by high-performance liquid chromatography using methods described earlier [7] with modifications (column size 250 mm). Drug was detected using ultraviolet spectroscopy at 205 nm. Unknown concentrations in samples were quantified by comparison with standards prepared with known amounts of levetiracetam (Keppra, UCB Pharma Inc., Smyrna, Georgia, USA).
Data analysis
For each time point, drug concentration data were averaged (n = 2-5). Composite drug concentration versus Concentrations are in mg/ml except for diazepam, which is expressed in ng/ml. Half-lives for immature mice are compared with values in mature mice [7] [8] [9] [10] [11] and in humans [12] . Plasma concentrations reach therapeutic levels in rodents [13, 14] and are compared with human values [12] . (Fig. 1) . Half-lives calculated from these serum concentrations were greater than their respective values in adult mice (Table 1) .
Each drug had a different degree of penetration of the blood-brain barrier ( Table 2 ). We found that 4 h after intraperitoneal injection of these antiepileptic drugs, brain-to-blood ratios were comparable with data in adult rodents.
Discussion
This study found that in comparison with adult mice, immature P19 mice metabolized the five studied anticonvulsant drugs slower. In these mice, the anticonvulsants yielded longer half-lives and were at or above therapeutic plasma concentrations for extended periods. Human infants have been shown to be hypometabolic compared with adults [4] . Antiepileptic drugs are administered chronically into neonates presenting with seizures at doses designed to maintain therapeutic trough concentrations. We examined the feasibility of similar experimental dosing regimens that would accomplish this goal in immature CD1 mice. We found that although all drugs had longer half-lives, only diazepam, phenobarbital, and phenytoin could plausibly follow a clinically relevant protocol with one or two injections daily. Diazepam with its metabolites had the greatest difference, with a halflife of 22.3 h compared with 7.7 h in adult mice [8] .
Loscher [13] has discussed earlier a three times daily injection regimen for controlling seizures in rodents, highlighting the caveat of a requisite half-life of at least 5 h for the anticonvulsants. With higher dose administration and repeated dosing, a half-life of approximately 5 h could possibly be achieved with levetiracetam and valproate in immature mice. Their half-lives are approximately 3 h after a single dose, and the half-life of valproate is known to increase with repeated dosing in adult rodents. More work is planned with higher repeated doses to determine this.
Generally, brain-to-blood ratios were comparable with those reported in mature mice. The immature bloodbrain barrier develops throughout the postnatal period with maturation of the characteristic cerebral endothelial tight junctions [15, [19] [20] [21] . Drug transporters develop concurrently. P-glycoprotein, a drug efflux transporter which acts on phenytoin, phenobarbital, and levetiracetam, is first detected in the rat brain at P7 and gradually increases to plateau at adult levels around P28, analogous to the developmental pattern within late gestational and neonatal humans [22, 23] . The main factors for penetration of the blood-brain barrier in the mature brain are lipid solubility and the dissociation constant of the compound in question [24] . Therefore, ratios were not expected to vary widely between adults and the P19 immature mice. The discrepancy between the phenytoin ratios reported here and ratios published earlier [17] can most likely be explained by the difference in dosing amounts, as phenytoin is known to accumulate in the brain. As diazepam and phenobarbital are very lipophilic, the increased amounts of lipids because of myelination in the adult brain could explain the greater concentrations of drug in the brain, and therefore higher brain-to-blood ratios compared with the immature rodents.
Conclusion
This study shows that a long-term clinical dosing strategy for anticonvulsants is feasible in immature CD1 mice. Antiepileptic drugs tested had longer half-lives and maintained therapeutic levels longer in the immature mice than in their mature counterparts. Blood-brain barrier penetration for all antiepileptic drugs in the study was similar to that reported in the mature rodent. Results from this study indicate that with a clinically relevant dosing protocol, therapeutic drug levels, in contrast to adult rodents, can be maintained in immature mice.
